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regeneration.[1–5]  Although protein thera-
peutics have exceptional potential for next-
generation therapies, delivery of these 
macromolecules is hindered due to their 
vulnerability to biological deactivation,[6–9] 
poor native membrane permeability, and 
short circulation time if utilized intrave-
nously.[10–12] For these reasons, the devel-
opment of protein delivery technologies 
is a vital endeavor that promises to unlock 
the potential of this significant class of 
bioactive macromolecules.[13,14]
An emerging strategy to address the 
challenge of protein delivery is via the use 
of coacervate particles, which is appealing 
due to their ability to spontaneously 
sequester various macromolecular car-
goes,[15,16] and to undergo direct cellular 
interactions.[17] In these terms, coacer-
vates have been described as biomimetic 
microcontainers due to their physico-
chemical semblance to the cell cytoplasm, 
albeit without an external membrane.[18,19] 
Although being a relative newcomer to 
the field of therapeutic protein delivery, 
coacervate-based materials have received 
significant attention in biomedical 
research and have already been used for drug delivery.[20,21] For 
example, coacervate-based materials have shown great promise 
for controlled growth factor delivery in vivo for attenuation of 
disc degeneration, persistent angiogenesis, preservation of 
The extent to which biologic payloads can be effectively delivered to cells 
is a limiting factor in the development of new therapies. Limitations arise 
from the lack of pharmacokinetic stability of biologics in vivo. Encapsulating 
biologics in a protective delivery vector has the potential to improve delivery 
profile and enhance performance. Coacervate microdroplets are developed as 
cell-mimetic materials with established potential for the stabilization of bio-
logical molecules, such as proteins and nucleic acids. Here, the development 
of biodegradable coacervate microvectors (comprising synthetically modified 
amylose polymers) is presented, for the delivery of biologic payloads to cells. 
Amylose-based coacervate microdroplets are stable under physiological con-
ditions (e.g., temperature and ionic strength), are noncytotoxic owing to their 
biopolymeric structure, spontaneously interacted with the cell membrane, 
and are able to deliver and release proteinaceous payloads beyond the plasma 
membrane. In particular, myoglobin, an oxygen storage and antioxidant pro-
tein, is successfully delivered into human mesenchymal stem cells (hMSCs) 
within 24 h. Furthermore, coacervate microvectors are implemented for the 
delivery of human bone morphogenetic protein 2 growth factor, inducing dif-
ferentiation of hMSCs into osteoprogenitor cells. This study demonstrates the 
potential of coacervate microdroplets as delivery microvectors for biomedical 
research and the development of new therapies.
1. Introduction
Due to their low cytotoxicity, high specificity, and activity, pro-
tein-based biologics are a rapidly expanding class of therapeutic 
agents and are being developed for medical oncology and tissue 
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heart function after myocardial infarction and skin regenera-
tion.[22–26] Although such recent studies have demonstrated the 
physical advantages presented by coacervate-based materials 
in addressing cells in a specific manner, their development 
toward drug delivery applications is, as of yet, significantly 
underexplored.
From a practical perspective, the ability to spontane-
ously assemble coacervates in aqueous solutions that actively 
sequester protein payloads is a major advantage of this tech-
nology. As this technology moves into the biomedical space, 
however, rationally designed coacervate systems with predict-
able and tunable behaviors need to be developed in order to 
identify the physicochemical determinants of therapeutic per-
formance. Two key physical factors underpinning coacervate 
performance are composition and stability in biological envi-
ronments. Accordingly, coacervates that can be engineered 
from biopolymeric building blocks benefit from inherent 
biocompatibility and their structure can be readily tailored by 
simple chemical modifications to ensure greater stability under, 
for example, physiological conditions (high salt and near neu-
tral pH).[27–29] In particular, the use of polysaccharides as a 
building block for therapeutic technologies exemplifies this 
logic,[30] and functionalization through derivatization has been 
described as a biocompatible route toward the development 
of bioactive materials.[31] Recently, coacervates upon amylose 
derivatives have been utilized as a platform for the engineering 
of hierarchical protocells, which present biofunctionality and 
physiological stability.[32,33]
With this in mind, we explore the utility of functionalized 
amylose-based coacervates as protein-delivery microvectors. 
We show that the physicochemical properties of amylose coac-
ervate microdroplets can be readily adjusted by simply var-
ying the constituent stoichiometry, leading to microdroplets 
with either positive or negative surface charge densities. The 
resulting microvectors are stable under physiological condi-
tions, noncytotoxic and can be used to deliver a range of protein 
payloads via spontaneous fusion with the plasma membrane 
of human mesenchymal stem cells (hMSCs). Finally, we dem-
onstrate that the oxygen storage protein myoglobin (Mb) can 
be delivered into the cytoplasm of hMSCs within 24 h, and 
that microvectors loaded with bone morphogenetic protein 
2 (BMP2) drove in vitro differentiation of hMSCs into osteo-
progenitors. Thus, our amylose-based coacervate microdrop-
lets can be suitable for a range of drug delivery applications, 
including in vivo localized delivery.
2. Results and Discussion
In previous work, we demonstrated that complex coacervate 
microdroplets comprising poly(diallyldimethylammonium 
chloride) and adenosine triphosphate (ATP) could be directly 
manipulated using optical tweezers to deliver molecular pay-
loads without undermining cellular integrity or function.[17] 
Although this microdroplet system represented a step in the 
right direction for coacervate-based vector development, it uti-
lized an industrially derived synthetic polymer and had only 
moderate droplet stability in cell media. Accordingly, here we 
look to develop the versatility of coacervate microdroplets and 
explore the principal physicochemical factors that determine 
their performance in cellulo. Critical factors in the utility of 
coacervates for cell-based therapies are their biocompatibility, 
stability under physiological conditions, such as ionic strength, 
and the ability to deliver functional payloads to and across the 
plasma membrane.[21]
2.1. Synthesis and Physical Characterization of the Coacervate 
Microvector
Capturing developments in the area of synthetic cellularity 
and reapplying them in a biomedical context is something of 
a cycle in the conceptual evolution of bioinspired materials. 
The advantage of using synthetically functionalized biopolymer 
components for the fabrication of coacervate microdroplets is 
the ability to tune their stability by systematically modifying 
charge density, which will affect the “stickiness” by modulating 
the magnitude and frequency of electrostatic interactions (both 
internally and externally). Synthetic coacervate microdroplets 
comprising modified amylose (a linear biopolymer) provides an 
exciting platform that can be applied to the controlled delivery 
of macromolecular cargos to cells. Having been established as a 
technology for the engineering of biocompatible synthetic proto-
cells, amylose-coacervates have demonstrated enhanced stability 
under increased ionic strength.[33] Accordingly, the components 
for complex coacervate microdroplets of both quaternized 
amylose (QA) or carboxymethylated amylose (CMA) variants, 
with positive or negative charges, respectively, were synthe-
sized upon modification of amylose polymer using a protocol 
adapted from Amar-Lewis et  al.[34] (Figure  1). Here, coacervate 
microdroplets were formed due to the electrostatic interaction 
between polyelectrolyte chains, driven by phase separation of 
the partially neutralized complexes into a polymer-rich (coacer-
vate) state. Having synthesized highly charged amylose deriva-
tives with a degree of substitution (DS) of 1 (QA1/CMA1) (Figure 
S1, Supporting Information), we initially ensured that the phase 
diagram for coacervate formation was broad enough to generate 
stable coacervate droplet dispersions over a wide range of QA1/
CMA1 stoichiometries. Indeed, the coacervate formation, as 
indicated by the onset of solution turbidity, between QA1/CMA1 
components was clearly evident in all mixing stoichiometries 
up to ≈90% (Figure 2a). In order to demonstrate its ability to 
tailor the overall charge of this system, the effect of various stoi-
chiometries was compared upon zeta-potential for the mixture 
of QA1 with either CMA1 or half-substituted CMA0.5 (Figure 2b). 
As expected, the equally charged mixtures of QA1/CMA1 fol-
lowed an almost sinusoidal curve with zero charge at the equi-
molar mark that became positively/negatively charged when 
there was an excess of QA1/CMA1, respectively. By contrast, the 
mixture of QA1/CMA0.5 showed an overall positive charge over 
the entire mixing range, due to the chemically programmed 
charge imbalance between the two components.
In order to favorably interact with anionic sulphated proteo-
glycans on the cell plasma membrane, the coacervate microdro-
plets need to be engineered to exhibit positive surface charge 
density at pH 7.3. Thus, the cationic coacervate microdroplets 
comprising QA1/CMA0.5 of 1:1 and 2:1 volume ratios were 
readily prepared in solution, respectively. These coacervate 
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microdroplets were assessed for their stability under physiolog-
ical conditions in terms of temperature and ionic strength. The 
stability of coacervate microdroplets comprising QA1/CMA0.5 of 
1:1 was not undermined at the elevated temperature of 37 °C, 
however, the 2:1 stoichiometry did show a reduction in turbidity 
(Figure S2a, Supporting Information). It is crucial to generate 
coacervate complexes with positive charges upon introducing 
the two components of 1:1 ratio, as such balance of charges 
within the coacervate complex would allow for simultaneous 
preservation of sufficient charged sites on each component, to 
ensure high stability of the complex when interacting with the 
cell membrane in presence of other charged species, such as 
salts. This was demonstrated using coacervate microdroplets 
comprising QA1/CMA0.5 of 1:1, which maintained highly stable 
in cell media at the physiological ionic strength (Figure S2b, 
Supporting Information). Accordingly, a QA1/CMA0.5 of 1:1 was 
used for all the subsequent studies. These stable microdroplets 
were of size around 1–5 µm (average 2–2.5 µm, Figure 2c).
2.2. Protein Sequestration Capacity of the Coacervate 
Microvector
The ability of coacervate microdroplets to actively sequester 
macromolecular cargos is a key facet of its interest as a model 
protocell and is a significant mechanism by which this structur-
ally complex phase of matter can be imbued with higher-order 
functionality.[16,23–25,35–39] The capacity of our coacervate micro-
droplet system to sequester protein payloads of different sizes 
and charges was next explored and the impact of this on droplet 
stability, charge and size was also studied. Three functional pro-
tein models were selected in this study: enhanced green fluores-
cent protein (eGFP, MW = 30.7 kDa, pI = 6.26) and cationized 
enhanced green fluorescent protein (cGFP, MW = 32.5  kDa, 
pI = 10.40), both for cell labeling and tracking; and myoglobin 
(Mb, MW = 16.9  kDa, pI = 6.97) labeled with N-hydroxy-suc-
cinimidyl (NHS)-fluorescein isothiocyanate (FITC), which can 
facilitate oxygenation and detoxification of cells (Figure S3, 
Supporting Information).[40] The coacervate microdroplets were 
formed as evident via transmitted light detection, and the spon-
taneous sequestration of all three proteins into the coacervate 
phase was observed (Figure  3a). The distribution of proteins 
was homogenous throughout the coacervate microdroplets, 
though some aggregation of cGFP was observed as well as the 
high background fluorescence, which signified lower levels of 
partitioning. This observation was supported by evaluating pro-
tein-coacervate partition coefficients, which were 1200 (± 500) 
for eGFP, 10 (± 3) for cGFP and 35 (± 11) for Mb, respectively 
(Figure  3b). The affinity of the protein components with the 
coacervate could be understood from the zeta-potential values 
of the individual components (Figure S4a, Supporting Informa-
tion), whereby the highly positively charged QA1 would strongly 
interact with CMA0.5, eGFP, and Mb that were all negatively 
charged and CMA0.5 would interact with positively charged 
cGFP. Protein loading into the coacervates altered the droplet 
zeta-potential except for Mb (Figure S4b, Supporting Informa-
tion) and all the coacervate microdroplets, regardless of the 
charges of proteins sequestered, maintained positive surface 
potential. A small increase in the average diameter of coacer-
vate microdroplets was observed after sequestration of all three 
proteins when compared to the unloaded control (Figure S4c, 
Supporting Information).
The partitioning coefficient of eGFP did not greatly change 
with pH, with uptake least effective near the protein pI and 
increasing by ≈10% at low or high pH values in response the 
overall charge of the protein, improving interactions with the 
coacervate phase (Figure S5a, Supporting Information). At 
elevated ionic strength (particularly above 0.5 m), eGFP was 
released in a nonlinear manner due to destabilization of the 
coacervate microphase (Figure S5b, Supporting Information). 
At least 70% of the eGFP sequestered remained within micro-
droplets at an ionic strength of 0.18 m, equivalent to that of cell 
culture media. Interestingly, the release of the sequestered pay-
load (eGFP) from the coacervate phase could be induced by the 
Figure 1. Schematic outlining the chemical composition of amylose-based, biopolymeric coacervate microdroplets, and their ability to spontaneously 
sequester biologic cargos, transporting them to cells as a new mode of therapeutic protein delivery.
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addition of α-amylase, which was capable of digesting the syn-
thetically modified amylose chains within 3 h at a concentration 
of 5 U mL−1 (Figure S6, Supporting Information), and indicated 
that the system could be developed for smart vectors with trig-
gered release profiles. The capacity of the coacervate microdro-
plet system to sequester multiple proteins simultaneously was 
also investigated. Dual-sequestration ability of eGFP and Mb was 
observed by confocal microscopy images (Figure S7, Supporting 
Information). This result showed a feature of our coacervate 
microdroplet system across a range of complex compositions, 
with a potential application of delivering a combination of two or 
three protein-based therapeutics with improved efficacy.[24]
2.3. Interaction of Coacervate Microvector with hMSCs
Having studied the important physicochemical properties of 
amylose-based coacervates, we then sought to explore their 
interactions with cells and capacity to deliver protein payloads. 
The potential cytotoxicity of coacervate microdroplets was 
estimated by performing cell metabolic assays (3-(4,5-dimeth-
ylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium; MTS) on bone marrow-derived hMSCs. 
Importantly, hMSCs showed no obvious decrease in cell via-
bility (>93.0%) as a result of exposure to most of the individual 
coacervate components (QA1/CMA0.5), empty coacervate micro-
droplets or those loaded with protein cargos (eGFP, cGFP, and 
Mb) (Figure 4a). The nontoxicity of this coacervate microdroplet 
system is expected given the biopolymeric nature of the con-
stituent components.
In order to explore the cellular partitioning of the coacervate 
components in greater detail, the locations of each individual 
coacervate component were tracked by fluorescein (FITC) labe-
ling after the delivery, performed 3 and 24 h after introduction 
of the coacervate microdroplets to hMSCs in media (Figure 4b). 
The positively charged QA1 was observed to promptly interact 
with hMSCs, showing spontaneously membrane binding ability 
within 3 h and internalization within 24 h after delivery. Con-
versely, the anionic coacervate component, CMA0.5, was found 
to persist locally at the area of the initial interaction for 24 h. 
This indicates that the two coacervate components, although 
they bind strongly enough to withstand the ionic strength of 
media, dissociate after being in contact with cells for over 3 h—
an important property that can facilitate delivery (release) of 
cargo. No evidence of internalization of either component into 
nucleus was observed.
2.4. The Delivery of Protein Payloads to hMSCs
As a proof-of-principle experiment for the delivery of functional 
biologics into the cell, we studied the potential for cellular 
delivery of coacervate microdroplets loaded with NHS-FITC-
labeled Mb (FITC_Mb). Here, the delivery of coacervate-seques-
tered protein was monitored with live cell imaging at 5 min, 3 
and 24 h after introduction of the loaded microdroplets. Free 
FITC_Mb had no inherent affinity for hMSCs and showed no 
binding to the plasma membrane (Figure 5a). In stark contrast 
to this, we observed a significant increase in protein localiza-
tion at the cell membrane after administration of the coacervate 
delivery system, which reflected the punctuated nature of micro-
droplet “paintballing” of the cell (Figure 5b). After 3 h FITC_Mb 
Figure 2. Synthesis and biophysical characterizations of amylose-based 
coacervate microdroplets. a) A heat map showing the turbidity for varying 
stoichiometries of two amylose components, quaternized amylose (QA1) 
and carboxymethylated amylose (CMA1) with a degree of substitution of 
1. The color bar on the right shows a scale of all colors from the map 
with their corresponding turbidity value. b) Zeta potential of non-resus-
pended coacervate systems of QA1/CMA1 (blue) and QA1/CMA0.5 (red). 
The squares and the triangles represent the mean average and the error 
bars represent the standard deviation (n = 6). c) The size distribution of 
unloaded coacervate microdroplets at room temperature, determined by 
analyzing acquired widefield images of microdroplets using Fiji software. 
Both CMA and QA were prepared in Milli-Q water at 1 wt% at pH 7.4.
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began to disperse on the cells with an evidence of internaliza-
tion into punctuated endosomal structures in a fashion similar 
to QA but more pronounced (Figure 5c). After 24 h of incuba-
tion, the functional protein had been fully internalized by the 
cells and channeled into endo-lysosomal compartments as indi-
cated by their highly regular, punctuated pattern (Figure  5d). 
We propose that coacervate-mediated delivery of protein cargo 
occurred through localized concentration and clustering at the 
plasma membrane, likely via an endocytic mechanism,[29,41] 
under the influence of cationic QA that interacts with the ani-
onic outer membrane (cf. Figure 4b). The delivery mechanism 
is more dependent on the surface charge and stability of the 
coacervate, rather than the size,[42], i.e., strong interactions with 
the plasma membrane can deform soft membrane-free coac-
ervate microdroplets.[43] From these results, we can clearly see 
that the coacervate-mediated delivery of protein cargos provides 
a substantial increase over the background level of uptake in 
the solution-phase and the physical control achieved using this 
method constitutes a major step in the development of new 
platforms to enable cellular reprogramming.
2.5. Controlled hMSC Differentiation Induced  
by Coacervate-Sequestered Growth Factor
In light of the effect protein delivery to the plasma mem-
brane and the cytosol, and as a final demonstration of utility 
for this coacervate microdroplet system, recombinant human 
BMP2 was partitioned into the coacervate microdroplets and 
the system tested as a potential microvector for growth fac-
tors. BMP2 acts as a master regulator that can induce osteo-
genic differentiation of hMSCs and stimulate the expression of 
essential markers at different developmental stages, including 
osteoblast runt-related transcription factor 2 (RUNX2), an pri-
mary osteogenic marker,[44] and alkaline phosphatase (ALPL), 
an early osteogenic marker.[45] Quantitative analysis of the dif-
ferentiation potential of coacervate microvectors was assessed 
via quantitative polymerase chain reaction (qPCR) after a one-
week differentiation process. Here, the expression levels of 
RUNX2 were monitored via comparison with the housekeeping 
gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH).[46] 
The 6.8-fold upregulation in expression of RUNX2 showed suc-
cessful initial differentiation of hMSCs into osteoprogenitors 
upon exposure to coacervate complexes loaded with 1.7 µg mL−1 
of BMP2 (Figure 6a). A slightly higher 7.8-fold upregulation of 
RUNX2 was found in the cells exposed to complete differen-
tiation media, which is believed due to a time-dependent effect 
of cell exposure to BMP2. Since the BMP2 receptors localize at 
the cell membrane,[47] cells directly exposed to free BMP2 could 
potentially initialize the differentiation process earlier than 
those treated with the coacervates, as free BMP2 would dif-
fuse faster in media than the microdroplets, and BMP2 has to 
also diffuse through the coacervate phase in the microdroplets. 
Accordingly, the expression of RUNX2, which acts as a primary 
Figure 3. Protein sequestration of coacervate microdroplets. a) Live cell confocal fluorescence microscopy images of sequestered enhanced green 
fluorescent protein (eGFP, green), cationized enhanced green fluorescent protein (cGFP, green), and myoglobin (Mb, labeled with NHS-FITC, green) 
in the coacervate microdroplets. Scale bars = 20 µm. b) The sequestration rates for eGFP, cGFP, and Mb, determined by comparing the absorbance of 
unsequestered proteins in the supernatant to the original solutions using UV–vis spectroscopy. The solid straight line represents the linear regression 
trend of the data, and the dotted curve on each side of the trend line represents the 95% confidence interval.
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transcription regulator of osteogenesis, could be triggered first 
and accumulated quickly upon the BMP2 treatment.[48,49]
The differentiation indication was further supported with 
upregulation of both ALPL gene expression (Figure 6b) and pro-
tein expression tested using a colorimetric assay (Figure 6c).[50] 
Here, expression levels of both ALPL gene and protein were sig-
nificantly increased in the hMSCs exposed to coacervate micro-
droplets carrying the BMP2 payload when compared to the cells 
treated with control basal media without BMP2, and compa-
rable to those in the complete differentiation media. Compared 
to RUNX2, ALPL is a relative later stage osteogenesis marker, 
the expression of which is regulated by both BMP2 and RUNX2 
and highly time-dependent.[48,49] The different expression levels 
of RUNX2 and ALPL at different time points during osteo-
genic differentiation process have also been observed by other 
groups.[51,52]
3. Conclusion
In this work, we rationally designed, built and characterized 
a novel complex coacervate microvector system for delivering 
proteins to cells, which spontaneously interacted with the 
plasma membrane of hMSCs and released the sequestered 
payloads. This coacervate microdroplet system is stable under 
physiological pH, ionic strength, and temperature and a range 
of proteins with different sizes and charges could be success-
fully sequestered. Particularly, Mb was delivered to the mem-
brane of hMSCs and internalized within the cells. Significantly, 
Figure 5. The interaction of protein-loaded coacervate microdroplets with 
human mesenchymal stem cells (hMSCs) over time. Live cell confocal fluores-
cence microscopy images showing hMSCs incubated with media containing 
a) free myoglobin (Mb) after 5 min, or Mb-loaded coacervate microdroplets 
after b) 5 min, c) 3 h, and d) 24 h. Cell cytoplasm was stained with a Cell-
Tracker Red CMTPX Dye (red) and cell nuclei were stained with a Hoechst dye 
(blue). Mb was labeled with NHS-FITC (green). Scale bars = 20 µm.
Figure 4. The interaction of coacervate microdroplets with the human 
mesenchymal stem cell (hMSC) plasma membrane. a) hMSC viability as 
a function of low (90 microdroplets per cell, 2.5 × 10–3 µg µL−1 of CMA0.5 
or QA1 (≈0.16 × 10−6–0.21 × 10−6 m), gray), medium (180 microdroplets 
per cell, 5 × 10–3 µg µL–1 of CMA0.5 or QA1 (≈0.32 × 10−6–0.42 × 10−6 m), 
blue), and high (1800 microdroplets per cell, 5 × 10–2 µg µL–1 of CMA0.5 
or QA1 (≈3.2 × 10−6–4.2  × 10−6 m), red) incubation concentrations of 
individual coacervate components and coacervate microdroplets with 
sequestered proteins, determined by 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. 
The bars represent the mean average and the error bars represent the 
standard deviation calculated using hMSCs from three different patients 
(n = 3). Statistical significance was calculated using a two-way ANOVA test 
with Bonferroni post-tests. A p-value of less than 0.05 and 0.01 considered 
significant (*) and highly significant (**), respectively, when compared to 
the cells treated with H2O. b) Live cell confocal fluorescence microscopy 
images showing the cell membrane affinity of FITC-labeled QA1 (green) 
or FITC-labeled CMA0.5 (green) in hMSCs, respectively, imaged after 3 h 
post incubation with coacervate microdroplets (with only one component 
labeled) for 15 min, and after a further 24 h. Cell cytoplasm was stained 
with a CellTracker Red CMTPX Dye (red) and cell nuclei were stained with 
a Hoechst dye (blue). Scale bars = 20 µm.
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sequestration of BMP2 into the coacervate system and sub-
sequent cell treatment induced osteogenic differentiation of 
hMSCs. Accordingly, our coacervate microvector system could 
be readily adapted to other proteins, regardless of their native 
affinity to the cell membrane, which could have major implica-
tions for biologics development.
4. Experimental Section
Amylose Modification and Characterization: Amylose was purchased 
from Carbosynth (UK) (MW = 12–16  kDa, n  = 74–79) and all other 
chemicals used for modification purposes were purchased from Sigma-
Aldrich (UK) and used without further purification. Q-amylose (QA) 
with a degree of modification (DM) of 1 (1 modification per anhydrous 
glucose unit, QA1) was prepared by dissolving 1.5  g of amylose and 
2.1  g of sodium hydroxide in 27  mL of Milli-Q water at 35 °C. After 
complete dissolution of the amylose, 4 mL of (3-Chloro-2-hydroxypropyl)
trimethylammonium chloride (CHPTAC) solution (60 wt% in water) 
was added dropwise into the stirring reaction mixture, which was 
subsequently left to react overnight. After the reaction was completed, 
the mixture was neutralized with acetic acid and precipitated into 
200  mL of cold ethanol. The resulting precipitate was redissolved in 
Milli-Q water and dialyzed extensively against water using regenerated 
cellulose dialysis tubing (Spectrum Labs, USA) with a molecular weight 
cut-off (MWCO) at 3.5 kDa.
CM-amylose with a DM of either 1 or 0.5 (CMA1 and CMA0.5) was 
prepared by dissolving 1.5 g of amylose and 3.6 g of sodium hydroxide 
in 15  mL of Milli-Q water at 70 °C. After complete dissolution of the 
amylose, 2.7 g (CMA1) or 1.8 g (CMA0.5) of chloroacetic acid was added 
and the reaction mixtures were left to stir for 2 h. After the reaction was 
completed, the mixture was neutralized with acetic acid and precipitated 
into 200 mL of cold ethanol. The resulting precipitate was redissolved in 
Milli-Q water and dialyzed extensively against water using regenerated 
cellulose dialysis tubing with a 3.5 kDa MWCO (Spectrum Labs, USA), 
and freeze-dried.
NMR Spectroscopy: 1H-NMR spectroscopy measurements were carried 
out to assess the DS. Samples were dissolved in the Milli-Q water at a 
concentration of 20 mg mL−1 and loaded into quartz NMR tubes. Proton 
NMR data were collected on a Varian 400 NMR spectrometer (Agilent 
technologies, UK) at 25 °C with 32 scans and a relaxation delay of 5 s, 
and the spectrum was integrated to find number of amylose, acetate 
group, and CHPTAC protons.
FITC Labeling QA and CMA: FITC-labeled QA and CMA were 
synthesized by dissolving either component in Milli-Q water with 5% 
NaOH and five equivalents of FITC to react with the hydroxyl groups 
on the polymers at high pH overnight. After this time, the solution was 
precipitated into ethanol and then dialyzed extensively.
Coacervate Preparation: CMA and QA were both prepared in Milli-Q 
water at 1 wt%. Both stock solutions were found to have pH of 7.4. The 
Figure 6. Directed differentiation of the human mesenchymal stem cell (hMSCs) induced by bone morphogenetic protein 2 (BMP2) delivery of coacervate 
microdroplets. The upregulation in a) runt-related transcription factor 2 (RUNX2) and b) alkaline phosphatase (ALPL) expression of osteoprogenitors 
induced by treating hMSCs with complete differentiation media supplemented with BMP2 (blue) or coacervate microdroplets with sequestered BMP2 (red) 
for a week, compared to the cells treated with basal media without BMP2, determined by qPCR. c) The ALP expression of osteoprogenitors induced by 
treating hMSCs with empty coacervate microdroplets (gray), complete differentiation media supplemented with BMP2 (blue), and coacervate microdroplets 
with sequestered BMP2 (red) for a week, compared to the cells treated with basal media without BMP2 (white), determined by an ALP assay. The bars rep-
resent the mean average and the error bars represent the standard deviation calculated using hMSCs from three different patients (n = 3). Statistical signifi-
cance was calculated using a two-tailed Student’s t-test. A p-value of less than 0.05 and 0.01 considered significant (*) and highly significant (**), respectively.
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coacervate phase was synthesized by combining equivalent volumes 
of each polymer solutions and Milli-Q water. Any payload materials to 
be sequestered into the coacervate system were introduced at desired 
concentrations in place of Milli-Q water. The system was and vortexed 
for 10 s and subsequently isolated by centrifugation at 4300 RCM for 5 
min into coacervate bulk phase and removal of supernatant. Coacervate 
pellet was resuspended in Milli-Q water by vortexing for 30 s, creating 
more stable coacervate microdroplets and removing any uncomplexed 
components. The final concentration of 8.3 × 10−12 µg per microdroplet 
was calculated for each polymer.
Coacervate Microdroplet Turbidity: The turbidity of the solution 
upon formation of complex coacervates was assessed by measuring 
absorbance (A) at 500  nm using UV–vis spectrophotometry, which 
was directly proportional to the scattering caused by turbid solutions. 
Collected absorbance readings were converted to corresponding 
turbidity using Equations (1). The turbidity for a range of stoichiometries 
was obtained by varying volumes of QA and CMA independently of 
each other between 0 and 100 µL with Milli-Q water added to make the 
volume up to 300 µL. Similarly, the stability of coacervate microdroplets 
was assessed in a range of media concentrations, using Dulbecco’s 









Protein Expression and Purification: eGFP was expressed in house, 
using BL21 competent Escherichia coli (New England Biolabs, USA)., 
transformed with the plasmid vector pET45b(+) (Novagen, Germany). 
The transformed E. coli was introduced in 10 mL of lysogeny broth (LB) 
with 10 µL of 50 mg mL−1 carbenicillin (Apollo Scientific, UK) for a starter 
culture. The sample was incubated overnight at 37 °C and stirred at 180 
RPM in a shaking incubator. The resulting culture was added to 1 L of 
LB medium with 1  mL of 50  mg mL−1 of carbenicillin and incubated 
at 37 °C with 200 RPM for 2 h. Bacterial growth was monitored using 
UV–vis spectrometer by measuring optical density (OD) at λ = 600 nm, 
until it reached 0.6–0.8. Protein expression was induced using 1  mL 
of 1 m isopropylthiogalactosidase (Apollo Scientific, Japan) and the 
culture was subsequently incubated at 30 °C for 4 h, followed by a 
reduction of temperature to 16 °C for overnight expression. The cells 
were centrifuged at 4500 RCF for 35 min using a Sorvall RC6 Centrifuge 
(Thermo Scientific, UK).
The resulting cell pellet from each 1 L culture was resuspended in 
50 mL lysis buffer containing 50 × 10−3 m NaH2PO4, 300 × 10−3 m NaCl 
and 10  × 10−3 m imidazole adjusted to pH 8, followed by addition of 
50 µL of 0.1 m phenylmethylsulfonyl fluoride (PMSF) solution, a protease 
inhibitor. The lysis of the cells was performed using Polytron PT25000 
homogenizer (Kinematica, Germany) to release the contents of the cells 
into solution. After homogenisation, a further 50  µL of 0.1 m PMSF 
solution was added to the solution. The resulting lysate was centrifuged 
at 20 000 RCF for 40 min to remove cell debris. The supernatant was 
purified using a nickel–nitrilotriacetic acid (Ni–NTA) resin column, and 
the protein was eluted using an elution buffer consisted of 50  × 10−3 
m NaH2PO4, 300 × 10−3 m NaCl, and 250 × 10−3 m imidazole at pH 8, 
and was subsequently dialyzed into 20 × 10−3 m phosphate buffer using 
12–14  kDa MWCO dialysis tubing (Medicell International, UK). Finally, 
the purity was assessed using sodium dodecyl sulfate polyacrylamide gel 
electrophoresis.
Mass Spectrometry: Matrix-assisted laser desorption ionization time 
of flight mass spectrometry (Bruker, UK) was used to determine the 
mass to charge ratio of proteins. 2,5-dihydroxyacetophenone matrix was 
prepared by mixing 20 mg mL−1 of 2,4-dihydroxyacetophenone in ethanol 
with diammonium hydrogen citrate at a 3:1 volume ratio. To prepare an 
saturated solution of sinapinic acid, 1 mL of matrix solution containing 
a volume ratio of 70:30 water:acetonitrile with 0.1% trifluoroacetic acid 
was added to 20  mg of sinapinic acid. The protein was mixed at a 1:1 
volume ratio with either of the matrices, of which 2  µL was deposited 
onto a ground steel sample plate and allowed to air-dry. Multiple spectra 
were additively acquired between 10  and 50  kDa using FLEX Control 
software (Bruker, USA) and peaks in the spectra were identified using 
Origin software (OriginLab Corporation, USA).
eGFP Cationization: 5 mg mL−1 eGFP was added to 100 mg mL−1 of 
N,N′-dimethyl-1, 3-propanediamine at pH 7. The solution was stirred for 
4 h at pH 6.9, followed by addition of N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride, and finally left to stir for another 24 h 
at pH 6.6. The product was dialyzed into 20 × 10−3 m phosphate buffer.
Fluorescein Labeling of Myoglobin: NHS-FITC was prepared to a 
concentration 10 mg mL−1 in dimethyl sulfoxide and introduced in excess 
to myoglobin in HEPES buffer, at pH 7. The solution was incubated 
for 1 h at room temperature. Any nonreacted NHS-FITC was removed 
using Zeba spin desalting columns with a 7 kDa MWCO (Thermo Fisher, 
USA), which utilizes size-exclusion chromatography resin. The final 
product, NHS-FITC-labeled myoglobin (FITC_Mb), was stored in 20  × 
10−3 m HEPES buffer, at pH 7 at −20 °C.
Protein Sequestration Efficiency: The supernatant was analyzed 
for absorbance using Cary 60 UV–vis spectrophotometer (Agilent 
Technologies, UK) to quantify the mass of any uncomplexed myoglobin 
(510 nm) or eGFP and cGFP (488 nm) (Ms), and to determine the mass 
of sequestered guest species in the coacervate microdroplets (Mc). The 
partitioning coefficient was calculated as a ratio of sequestered mass of 









= = −  (2)
Zeta Potential: Mean zeta potential of coacervate microdroplets was 
obtained using ZetaSizer Nano ZS (Malvern Instruments, UK) and 
analyzed using ZetaSizer software (Malvern Instruments, UK). Zeta 
potential was measured at 25 °C with 10–100 runs per sample after a 
300 s equilibration.
Glass Surface Modification for Imaging: In order to minimize the effect 
of heavy wetting of coacervate microdroplets on glass surfaces due to 
their hydrophobic properties, glass surfaces were functionalized with 
2-[methoxy(polyethyleneoxy)propyl]trimethoxysilane (m-PEG-TMOS) 
(ABCR GmbH, Germany). Glass cover slips were bathed in 10 mL fresh 
2% PEG-toluene solution for 1 h and the coated glass cover slips were 
next washed in excess water and air dried.
Coacervate Microdroplet Size: Total volume of 300  µL of coacervate 
microdroplets was prepared using standard coacervate preparation 
method, where the coacervate bulk phase was resuspended in 300  µL 
of Milli-Q water. The resulting microdroplets were deposited on PEG-
coated glass cover slips, imaged by acquiring bright field images using 
a DMI 3000 inverted microscope (Leica, UK) in Wolfson Bioimaging 
Facility (Medical Sciences, University of Bristol). The image processing 
and statistical particle size analysis were performed using “analyze 
particle” tool of Fiji software. 5000 microdroplets were measured for 
each complex of which an average was determined.
Coacervate Microdroplets Imaging: All microscopy imaging was 
acquired at the Wolfson Bioimaging Facility (University of Bristol, 
UK) using a Leica SP8 confocal multilaser scanning coupled with DM 
I6000 inverted epifluorescence microscope (Leica, UK). Coacervate 
microdroplets were introduced onto the PEG-coated glass slides 
and imaged using DAPI fluorophore (ex. 340–380  nm, em. 430–480) 
for Hoechst, GFP fluorophore (ex. 450–490  nm, em. 510–550) for 
eGFP, cationized eGFP, and FITC-tagged molecules, and rhodamine 
fluorophore (ex. 510–560  nm, em. 565–605  nm) for rhodamine-tagged 
molecules. Images were captured using Leica LAS-X acquisition software 
(Leica, UK) and processed by Fiji software.
Protein Payload Release: Total volume of 300  µL of coacervate 
microdroplets was prepared using standard coacervate preparation 
method, where the coacervate bulk phase was resuspended in 250  µL 
of Milli-Q water, followed by addition of 50  µL of NaCl (0.0–1.0 m) or 
50  µL of α-amylase from Bacillus amyloliquefaciens (Sigma-Aldrich, 
UK) (0.25, 2.5, and 25 units g−1), with an incubation time of 3 and 
24 h. The control used 50  µL of Milli-Q water in place of the enzyme. 
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To quantify the release of eGFP from coacervate microdroplets upon 
exposure to the factors introduced, samples were centrifuged down 
to isolate supernatant for analysis with Mithras LB940 multimode 
microplate reader (Berthold Technologies, UK). Collected fluorescence 
and absorbance readings were subsequently converted to protein 
concentrations upon comparison to standard curve.
hMSC Culture: hMSCs were isolated, characterized, cultured, and 
passaged as previously described.[17]
Cell-Coacervate Microdroplet Interaction Imaging: A Leica SP8 AOBS 
confocal laser scanning microscope attached to a Leica DM I6000 
inverted epifluorescence microscope was used for live-cell imaging. 
Location of individual components as well as delivered payloads within 
cells was tracked by incubating hMSCs for 30 min in staining media 
containing 0.5 × 10−6 m Cell Tracker Red CMTPX (Life Technologies, USA) 
and Hoechst 33342 (Life Technologies, USA). The excitation filters used 
were DAPI fluorophore (360/40 nm) for Hoechst, GFP fluorophore (450–
490 nm) for cells labeled with the constructs and rhodamine fluorophore 
(515–560  nm) for cytoplasm. Images were captured using Leica LAS-X 
acquisition software (Leica, UK) and processed by Fiji software.
Cytoxicity Assays: Viability of hMSCs after exposure to coacervate 
material was measured by a 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) 
assay (Promega, USA). The hMCSs from three patients were plated in 
triplicates in 96 well plates, with 5000 cells per well, and incubated at 
37 °C overnight to adhere. 0, 500, 1000, 2500, 5000, 7500, 10 000, and 
15 000 cells were seeded per well under identical conditions for the 
standard curve. The cells were incubated with coacervate microdroplets 
for 15 mins at a range of concentrations of 90 (low), 180 (medium), 
and 1800 (high) microdroplets per cell, in FBS-free media, after which 
the media with free floating microdroplets was replaced with complete 
media supplemented with 10% FBS and incubation for a further 4 h. 
The viability of cells was assessed by replacing the media with 100  µL 
of phenol-free expansion media and 20  µL of CellTiter 96 AQ One 
Solution Reagent in each well. Cells were incubated at 37 °C for 3 h, 
and then 100 µL of supernatant was transferred to a 96 well plate before 
measuring absorbance at 490 nm using a plate reader (Mithras LB940 
plate reader, Berthold Technologies, USA). The number of living cells 
was converted using standard curve absorbance measurements.
In Vitro Osteogenic Differentiation of hMSCs: 133 000 hMSCs (passage 
number 1) from three patients were seeded into each well of 6 well 
plates and were allowed to attach for 24 h. 1  µL of 100  µg mL−1 BMP2 
was added in a total 60  µL of coacervate microdroplets and cells were 
treated with 1  µL of BMP2 loaded coacervate microdroplets in partial 
differentiation medium (α-MEM supplemented with NaHCO3, 0.01  × 
10−6 m dexamethasone ethanol, 0.25  × 10−3 m ascorbic acid, 0.01 m 
β-glycerophosphate) for 20 min and the medium was replaced with 
partial differentiation medium. The positive control groups were exposed 
to complete differentiation medium of α-MEM supplemented with 
NaHCO3, 100 × 10−6 m dexamethasone ethanol, 80 × 10−3 m ascorbic acid, 
1 m β-glycerophosphate and 100  µg mL−1 BMP2. The negative control 
groups were incubated only in basal medium of α-MEM. The cells were 
cultured for 1 week with medium change every other day, introducing 
freshly prepared BMP2-loaded coacervate microdroplets every time.
qPCR: Cells were lysed and total RNA was extracted using RNeasy 
Micro Kit (Qiangen, Germany), following the manufacturer’s 
instructions. RNA concentration of each sample was assessed using 
NanoDrop ND2000 (Labtech International, UK), followed by dilution 
of all samples down to a same concentration of 20  ng µL−1 with Easy 
Dilution Buffer, and addition of megamix (Takara, Japan). cDNA 
synthesis was performed by reverse transcription at 37 °C for 15 min, 
followed by inhibition of reverse transcription at 85 °C for 5 s and cooling 
down to 4 °C, using a Labcycler SensoQuest cycler machine (Geneflow, 
UK). Finally, cDNA samples were diluted in RNase-free water and added 
to qPCR wells together with RUNX2 or ALPL and Taqman mastermix 
(Life Technologies, UK), and compared against a housekeeping gene 
GAPDH. The gene amplification was conducted using StepOnePlus 
Real-Time PCR System (Applied Biosystems, USA) with the following 
steps; polymerase enzyme activation at 95 °C for 10 min and forty cycles 
of denaturation at 95 °C for 15 s and annealing of primers and extension 
at 60 °C for 1 min.
ALP Protein Colorimetric Assay: 15 000 hMSCs (passage number 1) from 
three patients were seeded into each well of 48 well plates for osteogenic 
differentiation using BMP2 loaded coacervate microdroplets. After a week, 
ALP protein expression was assessed using an ALP assay kit (GeneTex, 
UK), following the manufacturer’s instructions. The ALP enzyme convert 
4-methylumbelliferyl phosphate substrate to equal amount of fluorescent 
4-methylumbelliferone (4-MU) and the resulting fluorescence intensity of 
4-MU was measured using a plate reader (Biotek, USA) with excitation at 
360 nm and emission detection at 440 nm.
Statistical Analysis: Comparison of differences was tested using 
ANOVA and a two-tailed Student’s t-test with p-value of less than 
0.05 and 0.01 considered significant (*) and highly significant (**), 
respectively. Data presentation and sample size for each study were 
mentioned in the corresponding figures.
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